Company Overview - Monday.com (MNDY) is expected to report a year-over-year increase in earnings, with a projected EPS of $0.70, reflecting a change of +14.8% [3] - Revenues for the upcoming quarter are anticipated to be $275.66 million, which represents a growth of 27.1% compared to the same quarter last year [3] Earnings Expectations - The consensus EPS estimate has been revised 16.67% higher in the last 30 days, indicating a positive reassessment by analysts [4] - The Most Accurate Estimate for Monday.com is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.32%, suggesting a likelihood of beating the consensus EPS estimate [10][11] Historical Performance - In the last reported quarter, Monday.com exceeded the expected EPS of $0.78 by delivering earnings of $1.08, achieving a surprise of +38.46% [12] - The company has successfully beaten consensus EPS estimates in each of the last four quarters [13] Industry Context - In the Zacks Internet - Software industry, Affirm Holdings (AFRM) is also expected to report a loss of $0.08 per share, with a year-over-year change of +81.4% and projected revenues of $783.11 million, up 35.9% from the previous year [17] - Affirm Holdings has an Earnings ESP of 63.27% and a Zacks Rank of 1 (Strong Buy), indicating a strong likelihood of beating the consensus EPS estimate [18]

Microvast Holdings, Inc. (MVST) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on May 12, 2025, might help the stock move higher if these key numbers are bett ...

Company Overview - Orchestra BioMed Holdings, Inc. (OBIO) is expected to report a quarterly loss of $0.46 per share, reflecting a year-over-year decline of 21.1% [3] - Revenues are anticipated to be $0.39 million, down 37.1% from the same quarter last year [3] Earnings Expectations - The consensus EPS estimate has been revised 1.03% lower in the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for OBIO is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +1.64% [11] Earnings Surprise Prediction - A positive Earnings ESP reading suggests a higher likelihood of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [8] - The company currently holds a Zacks Rank of 3, indicating a moderate expectation of beating the consensus EPS estimate [11] Historical Performance - In the last reported quarter, OBIO was expected to post a loss of $0.43 per share and met this expectation with no surprise [12] - Over the past four quarters, the company has beaten consensus EPS estimates two times [13] Industry Context - Intellia Therapeutics, Inc. (NTLA), a peer in the Zacks Medical - Biomedical and Genetics industry, is expected to report an EPS of $1.26, reflecting a year-over-year decline of 18.9% [17] - NTLA's revenues are projected to be $14.5 million, down 49.9% from the previous year [17] - Despite a recent upward revision of 0.8% in NTLA's EPS estimate, it has a negative Earnings ESP of -4.93%, complicating predictions for an earnings beat [18]

Wall Street expects a year-over-year decline in earnings on lower revenues when SurgePays, Inc. (SURG) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock ...

Company Overview - Tango Therapeutics, Inc. (TNGX) is expected to report a quarterly loss of $0.34 per share, reflecting a year-over-year change of +2.9% [3] - Revenues are anticipated to be $6.27 million, which is a decrease of 3.1% from the same quarter last year [3] Earnings Expectations - Wall Street anticipates a year-over-year increase in earnings despite lower revenues, with the earnings report set to be released on May 12 [1][2] - The consensus EPS estimate has been revised 1.52% lower over the last 30 days, indicating a bearish sentiment among analysts [4][10] Earnings Surprise Prediction - The Most Accurate Estimate for Tango Therapeutics is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -2.19% [10][11] - The company currently holds a Zacks Rank of 4, which complicates the prediction of an earnings beat [11] Historical Performance - In the last reported quarter, Tango Therapeutics was expected to post a loss of $0.32 per share but actually reported a loss of $0.35, resulting in a surprise of -9.38% [12] - Over the past four quarters, the company has beaten consensus EPS estimates two times [13] Industry Comparison - Mirum Pharmaceuticals, Inc. (MIRM), another player in the Zacks Medical - Biomedical and Genetics industry, is expected to post a loss of $0.39 per share, indicating a year-over-year change of +27.8% [17] - Mirum's revenues are projected to be $98.47 million, up 42.3% from the previous year [17] - Despite a recent EPS estimate revision of 2.8% downwards, Mirum has a Zacks Rank of 2 (Buy) but an Earnings ESP of -4.27% [18]

United Parks & Resorts (PRKS) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Ma ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Essential Utilities (WTRG) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May 1 ...

Company Overview - Vital Energy (VTLE) is expected to report quarterly earnings of $2.11 per share, reflecting a year-over-year increase of +10.5% [3] - Revenues are anticipated to reach $532.28 million, which is a 10.4% increase from the same quarter last year [3] Earnings Expectations - The consensus EPS estimate has been revised down by 11.33% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Vital Energy matches the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [10][11] Historical Performance - In the last reported quarter, Vital Energy exceeded the expected earnings of $2.16 per share by delivering $2.30, achieving a surprise of +6.48% [12] - Over the past four quarters, the company has beaten consensus EPS estimates three times [13] Market Sentiment - The stock currently holds a Zacks Rank of 5 (Strong Sell), which complicates the prediction of an earnings beat [11] - Despite the potential for an earnings beat, other factors may influence stock movement, making it essential to consider broader market conditions [14][16] Industry Comparison - Fluence Energy, another player in the alternative energy sector, is expected to report a significant decline in earnings, with an EPS estimate of $0.21, reflecting a year-over-year change of -200% [17] - Fluence Energy's revenues are projected to decrease by 48.6% to $320.61 million, with a consensus EPS estimate revised down by 30.7% [18]

Marriott International, Inc. (MAR) is scheduled to release first-quarter 2025 results on May 6, before the opening bell. In the previous quarter, the company’s earnings beat the Zacks Consensus Estimate by 2.9%.MAR’s Trend in Estimate RevisionThe Zacks Consensus Estimate for first-quarter bottom line is pegged at $2.27, indicating growth of 6.6% from $2.13 reported in the year-ago quarter. In the past 30 days, earnings estimates have witnessed downward revisions of 0.4%. (See the Zacks Earnings Calendar to ...

Since the start of 2025, the United States construction sector has been navigating through choppy waters, hit by several unfavorable market factors, including a still-high mortgage rate scenario and an unhinged interest rate environment. With the 30-year mortgage rate lingering between 6.9% and 6.7% (during the January-March 2025 period), reaching as high as 7.04% for the week ending on Jan. 16, 2025, the residential construction market is likely to have remained soft, mainly for the multi-family starts. Ho ...